# Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria

> **NCT00561964** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 241 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Irbesartan
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00561964
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2007-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561964, "Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00561964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*